Bank of America’s Co-Diagnostics CODX Stock Holding History

Bank of America’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,630	Closed	-$2.11M	–	6922
2020 Q2	$2.11M	Buy	+3,630	New	+$1.66M	﹤0.01%	3584

Other funds holding CODX

PAG

Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

Smartleaf Asset Management Boston, Massachusetts $2.77B AUM 22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HWA

Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Bank of America's CODX Position: Q1 2026 in Review

Bank of America sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 17 shares — an estimated $85 sold.

Bank of America first reported a position in CODX in Q2 2019 and held it in 21 quarters. The position peaked at $2.36M in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

Bank of America reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 17 Co-Diagnostics shares in Q1 2026, an estimated $85.
Bank of America first reported a position in Co-Diagnostics in Q2 2019 and held it in 21 quarters.
Bank of America's Co-Diagnostics position peaked at $2.36M in Q2 2020.
14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.